Drugs Made In America Acquisition II Corp.
DMIIFinancial ServicesNASDAQShell Companies · Last scanned Oct 26, 2026
Scan Results
Daily timeframeDrugs Made In America Acquisition II Corp. operates in the Shell Companies space. Drugs Made In America Acquisition II Corp. The company carries a $649.1M market cap, placing it firmly in the small-cap category. does not have significant operations.
Market Cap
$649.1M
Beta
—
P/E (TTM)
33.97
P/E (Fwd)
—
EPS (TTM)
$0.30
EPS (Fwd)
—
ROE
—
ROA
—
Cash
$174,974
Total Debt
$450,000
Free CF
—
52W Change
3.1%
Annual Financials
Cash vs Debt
Where DMII stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, DMII finished 0.89% above its 150-day moving average ($10.09) and 1.29% above its 200-day moving average ($10.05). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is DMII overbought or oversold?
At the October 20, 2026 close, DMII's RSI(14) was 50.0, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $175K in cash, though total debt stands at $450K. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve.
Investors considering Drugs Made In America Acquisition II Corp. should weigh the typical risks associated with DMII's sector, size, and financial profile against their own risk tolerance and investment objectives. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Drugs Made In America Acquisition II Corp.'s trajectory.